LCM
PVLA icon

Legato Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Legato Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59M Buy
23,490
+7,467
+47% +$906K 0.3% 89
2026
Q1 		$2M Buy
16,023
+4,638
+41% +$484K 0.18% 168
2025
Q4 		$1.19M Buy
+11,385
New +$971K 0.1% 309

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Legato Capital Management's PVLA Position: Q2 2026 in Review

Legato Capital Management increased its Palvella Therapeutics (PVLA) stake by 47% in Q2 2026, buying an estimated $906K and bringing the position to 23,490 shares worth $3.59M. The position accounts for 0.3% of the portfolio, ranked #89.

Legato Capital Management first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Legato Capital Management held 23,490 shares of Palvella Therapeutics worth $3.59M as of Q2 2026.
  • Legato Capital Management bought 7,467 Palvella Therapeutics shares in Q2 2026, an estimated $906K.
  • Palvella Therapeutics made up 0.3% of Legato Capital Management's portfolio in Q2 2026, its #89 holding.
  • Legato Capital Management first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.